Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Vertex Pharmaceuticals Inc(VRTX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for VRTX
10/09/2026: VRTX (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Vertex Pharmaceuticals is a focused biotechnology leader primarily recognized for its portfolio of treatments for cystic fibrosis. The company utilizes a research-driven approach to develop specialty medicines, successfully translating scientific innovation into sustained revenue. Its primary investment story hinges on expanding beyond cystic fibrosis into new specialty markets, including gene editing and treatment for pain and kidney disease. Key risks include heavy reliance on a single therapeutic franchise, execution challenges in new markets, and regulatory pressure on drug pricing. Vertex may best suit growth-oriented investors who can tolerate biotech-specific volatility, with stakeholders encouraged to monitor clinical trial readouts and new product commercialization progress.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Vertex has a track record of growth driven by successful R&D and market penetration in niche therapeutic areas. |
| Momentum investor | Mixed fit | Momentum appeal depends on positive clinical trial readouts and regulatory catalysts. |
| Value investor | Weak fit | The stock often trades at a premium multiple reflecting its growth prospects rather than traditional value metrics. |
| Dividend investor | Weak fit | The company does not pay a dividend and focuses entirely on reinvestment. |
| Low-risk investor | Mixed fit | While established, biotechnology carries inherent clinical and regulatory risks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | Biotech stocks often react sharply to clinical data releases and regulatory decisions. |
| Valuation risk | Medium | The share price assumes continued success in clinical pipeline execution. |
| Competition risk (Gene therapy/Specialty) | Medium | Success attracts competitors to the same genetic and specialty disease indications. |
| Business quality | Strong | The company has a very strong market position in cystic fibrosis with high barriers to entry. |
| Dividend income | Low / none | There is no income generation for investors seeking dividends. |
| Execution risk | Medium | Transitioning from a CF-focused company to a broader specialty biotech requires successful delivery of new products. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type Stock | Historic Profit -10.48% | Avg. Invested days 53 | Today’s Advisory WEAK BUY |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/09/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 127.55B USD | Price to earnings Ratio 29.31 | 1Y Target Price 571.61 |
Price to earnings Ratio 29.31 | 1Y Target Price 571.61 | ||
Volume (30-day avg) 1.0M shares | Beta 0.28 | 52 Weeks Range 402.58 - 560.25 | Updated Date 10/09/2026 |
52 Weeks Range 402.58 - 560.25 | Updated Date 10/09/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 17.17 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Cystic Fibrosis Products | Trikafta, Symdeko, Orkambi, Kalydeco | The vast majority of the company's revenue comes from therapies treating the underlying cause of cystic fibrosis. |
| Geography | Global sales, primarily North America, Europe, and Australia | Sales are concentrated in developed markets with established healthcare reimbursement systems. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 29.31 | Forward PE 24.1 | Enterprise Value 125.00B | Price to Sales(TTM) 10.13 |
Enterprise Value 125.00B | Price to Sales(TTM) 10.13 | ||
Enterprise Value to Revenue 9.93 | Enterprise Value to EBITDA 24.51 | Shares Outstanding 253.46M | Shares Floating 252.68M |
Shares Outstanding 253.46M | Shares Floating 252.68M | ||
Percent Insiders 0.21 | Percent Institutions 98 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.